Pharming Group (PHARM.AS) Stock Price

Pharming Group Price

Euronext·CLOSED
1.29USD-0.01 (-1.03 %)
Market closed

Over the last 19 years Pharming Group grew revenue by 48.9% annually, reaching 329.63 M USD. Earnings per share have declined at 29.3% per year over the last 7 years. For Pharming Group, the net margin of 0.8% is down versus 8.4% a few years ago. The consensus 12-month price target for Pharming Group is 2.35 USD, about 82.4% above where the stock trades today. Of 14 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 17% above its 52-week low.

Pharming Group stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Pharming Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Pharming Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Pharming Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Pharming Group Stock Price History
DatePharming Group Price
6/19/20261.29 USD
6/18/20261.30 USD
6/17/20261.27 USD
6/16/20261.29 USD
6/15/20261.30 USD
6/12/20261.28 USD
6/11/20261.25 USD
6/10/20261.24 USD
6/9/20261.27 USD
6/8/20261.31 USD
6/5/20261.30 USD
6/4/20261.25 USD
6/3/20261.23 USD
6/2/20261.29 USD
6/1/20261.32 USD
5/29/20261.36 USD
5/28/20261.35 USD
5/27/20261.36 USD
5/26/20261.37 USD
5/25/20261.38 USD
5/22/20261.30 USD
5/21/20261.29 USD
5/20/20261.28 USD
5/19/20261.28 USD
5/18/20261.27 USD
5/15/20261.30 USD
5/14/20261.32 USD
5/13/20261.33 USD
5/12/20261.30 USD
5/11/20261.30 USD
5/8/20261.29 USD
5/7/20261.22 USD
5/6/20261.64 USD
5/5/20261.64 USD
5/4/20261.68 USD
4/30/20261.68 USD
4/29/20261.66 USD
4/28/20261.66 USD
4/27/20261.67 USD
4/24/20261.67 USD
4/23/20261.70 USD
4/22/20261.69 USD
4/21/20261.71 USD
4/20/20261.75 USD
4/17/20261.75 USD
4/16/20261.75 USD
4/15/20261.79 USD
4/14/20261.78 USD
4/13/20261.71 USD
4/10/20261.73 USD
4/9/20261.71 USD
4/8/20261.73 USD
4/7/20261.66 USD
4/2/20261.68 USD
4/1/20261.71 USD
3/31/20261.68 USD
3/30/20261.66 USD
3/27/20261.67 USD
3/26/20261.67 USD
3/25/20261.65 USD
3/24/20261.63 USD
3/23/20261.60 USD
3/20/20261.60 USD
3/19/20261.56 USD
3/18/20261.57 USD
3/17/20261.57 USD
3/16/20261.59 USD
3/13/20261.52 USD
3/12/20261.56 USD
3/11/20261.61 USD
3/10/20261.63 USD
3/9/20261.60 USD
3/6/20261.56 USD
3/5/20261.59 USD
3/4/20261.62 USD
3/3/20261.58 USD
3/2/20261.62 USD
2/27/20261.64 USD
2/26/20261.62 USD
2/25/20261.69 USD
2/24/20261.69 USD
2/23/20261.65 USD
2/20/20261.65 USD
2/19/20261.66 USD
2/18/20261.68 USD
2/17/20261.61 USD
2/16/20261.56 USD
2/13/20261.56 USD
2/12/20261.53 USD
2/11/20261.56 USD
2/10/20261.60 USD
2/9/20261.62 USD
2/6/20261.60 USD
2/5/20261.64 USD
2/4/20261.68 USD
2/3/20261.71 USD
2/2/20261.68 USD
1/30/20262.01 USD
1/29/20262.02 USD
1/28/20262.01 USD
1/27/20262.09 USD
1/26/20262.01 USD
1/23/20261.96 USD
1/22/20261.98 USD
1/21/20261.78 USD
1/20/20261.75 USD
1/19/20261.78 USD
1/16/20261.88 USD
1/15/20261.83 USD
1/14/20261.85 USD
1/13/20261.79 USD
1/12/20261.87 USD
1/9/20261.89 USD
1/8/20261.77 USD
1/7/20261.73 USD
1/6/20261.67 USD
1/5/20261.68 USD
1/2/20261.72 USD
12/31/20251.67 USD
12/30/20251.67 USD
12/29/20251.68 USD
12/24/20251.69 USD
12/23/20251.69 USD
12/22/20251.72 USD
12/19/20251.65 USD
12/18/20251.63 USD
12/17/20251.64 USD
12/16/20251.62 USD
12/15/20251.68 USD
12/12/20251.72 USD
12/11/20251.74 USD
12/10/20251.73 USD
12/9/20251.71 USD
12/8/20251.71 USD
12/5/20251.66 USD
12/4/20251.67 USD
12/3/20251.60 USD
12/2/20251.61 USD
12/1/20251.62 USD
11/28/20251.69 USD
11/27/20251.71 USD
11/26/20251.77 USD
11/25/20251.74 USD
11/24/20251.72 USD
11/21/20251.66 USD
11/20/20251.70 USD
11/19/20251.63 USD
11/18/20251.63 USD
11/17/20251.63 USD
11/14/20251.70 USD
11/13/20251.75 USD
11/12/20251.71 USD
11/11/20251.66 USD
11/10/20251.71 USD
11/7/20251.64 USD
11/6/20251.61 USD
11/5/20251.29 USD
11/4/20251.34 USD
11/3/20251.33 USD
10/31/20251.33 USD
10/30/20251.33 USD
10/29/20251.35 USD
10/28/20251.35 USD
10/27/20251.36 USD
10/24/20251.37 USD
10/23/20251.37 USD
10/22/20251.33 USD
10/21/20251.37 USD
10/20/20251.39 USD
10/17/20251.41 USD
10/16/20251.47 USD
10/15/20251.44 USD
10/14/20251.43 USD
10/13/20251.47 USD
10/10/20251.46 USD
10/9/20251.52 USD
10/8/20251.46 USD
10/7/20251.46 USD
10/6/20251.53 USD
10/3/20251.62 USD
10/2/20251.53 USD
10/1/20251.53 USD
9/30/20251.46 USD
9/29/20251.42 USD
9/26/20251.32 USD
9/25/20251.49 USD
9/24/20251.50 USD
9/23/20251.48 USD
9/22/20251.47 USD
9/19/20251.47 USD
9/18/20251.40 USD
9/17/20251.43 USD
9/16/20251.42 USD
9/15/20251.42 USD
9/12/20251.43 USD
9/11/20251.45 USD
9/10/20251.49 USD
9/9/20251.43 USD
9/8/20251.46 USD
9/5/20251.51 USD
9/4/20251.49 USD
9/3/20251.46 USD
9/2/20251.41 USD
9/1/20251.45 USD
8/29/20251.47 USD
8/28/20251.45 USD
8/27/20251.42 USD
8/26/20251.37 USD
8/25/20251.37 USD
8/22/20251.35 USD
8/21/20251.28 USD
8/20/20251.24 USD
8/19/20251.23 USD
8/18/20251.24 USD
8/15/20251.17 USD
8/14/20251.14 USD
8/13/20251.13 USD
8/12/20251.11 USD
8/11/20251.19 USD
8/8/20251.20 USD
8/7/20251.23 USD
Access this data via the Eulerpool API
Get Free API Key

Pharming Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
198.86 M USD
-17.86 M USD
-8.55 M USD
Jan 1, 2024
260.34 M USD
-2.98 M USD
-10.38 M USD
Jan 1, 2025
329.63 M USD
18.30 M USD
2.60 M USD
Jan 1, 2026 (e)
407.28 M USD
25.54 M USD
17.11 M USD
Jan 1, 2027 (e)
446.97 M USD
28.03 M USD
24.26 M USD
Jan 1, 2028 (e)
430.48 M USD
27.00 M USD
24.29 M USD
Jan 1, 2029 (e)
535.28 M USD
33.57 M USD
54.64 M USD
Jan 1, 2030 (e)
902.05 M USD
56.57 M USD
80.95 M USD

Pharming Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 11:42 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
10.0014.0094.00135.00165.00200.00166.00180.00198.00260.00329.00407.00446.00430.00535.00902.00
-54.5540.00571.4343.6222.2221.21-17.008.4310.0031.3126.5423.719.58-3.5924.4268.60
50.0071.4386.1783.7087.2788.5089.1691.1185.3588.0887.8487.8487.8487.8487.8487.84
5.0010.0081.00113.00144.00177.00148.00164.00169.00229.00289.00357.52391.78377.72469.95792.33
-12.00-10.0023.0031.0059.0071.0024.0015.00-17.00-2.0018.0025.0028.0026.0033.0056.00
-120.00-71.4324.4722.9635.7635.5014.468.33-8.59-0.775.476.146.286.056.176.21
-9.00-16.00-84.0025.0035.0033.0014.0011.00-8.00-10.002.0017.0024.0024.0054.0080.00
50.0077.78425.00-129.7640.00-5.71-57.58-21.43-172.7325.00-120.00750.0041.18–125.0048.15
408.68415.38500.41648.23648.23648.23641.00692.20675.00740.00758.92758.92758.92758.92758.92758.92
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Pharming Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Pharming Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Pharming Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Pharming Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Pharming Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Pharming Group stock margins

The Pharming Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pharming Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pharming Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
89.37 %
14.66 %
8.43 %
Jan 1, 2022
91.46 %
8.87 %
6.65 %
Jan 1, 2023
85.23 %
-8.98 %
-4.30 %
Jan 1, 2024
88.13 %
-1.15 %
-3.99 %
Jan 1, 2025
87.90 %
5.55 %
0.79 %
Jan 1, 2026 (e)
87.90 %
6.27 %
4.20 %
Jan 1, 2027 (e)
87.90 %
6.27 %
5.43 %
Jan 1, 2028 (e)
87.90 %
6.27 %
5.64 %

Pharming Group Stock Revenue, EBIT, Earnings per Share

The Pharming Group earnings per share therefore indicates how much revenue Pharming Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.26 USD
0.04 USD
0.02 USD
Jan 1, 2022
0.26 USD
0.02 USD
0.02 USD
Jan 1, 2023
0.29 USD
-0.03 USD
-0.01 USD
Jan 1, 2024
0.35 USD
-0.00 USD
-0.01 USD
Jan 1, 2025
0.43 USD
0.02 USD
0.00 USD
Jan 1, 2026 (e)
0.61 USD
0.03 USD
0.03 USD
Jan 1, 2027 (e)
0.67 USD
0.04 USD
0.04 USD
Jan 1, 2028 (e)
0.64 USD
0.04 USD
0.04 USD

Pharming Group business model & stock analysis

Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide.

Pharming Group SWOT Analysis

Strengths

1. Established track record: Pharming Group NV has a strong history of developing and launching successful pharmaceutical products.

2. Innovative research and development: The company invests heavily in R&D, which allows it to stay at the forefront of advanced medical therapies.

3. Strong intellectual property portfolio: Pharming Group NV holds numerous patents for its products, providing a competitive advantage in the market.

Weaknesses

1. Dependence on limited product portfolio: The company heavily relies on a few key products for its revenue, leaving it vulnerable to market fluctuations.

2. Regulatory challenges: The pharmaceutical industry is heavily regulated, and any changes in regulations or delays in obtaining approvals can impact Pharming Group NV's operations.

3. High research and development costs: While investment in R&D is a strength, it also presents a financial burden for the company, potentially affecting profitability.

Opportunities

1. Market expansion: Pharming Group NV can explore new markets and regions to increase its customer base and revenue streams.

2. Collaborations and partnerships: Forming strategic alliances can help the company access new technologies, expertise, and distribution channels.

3. Growing demand for rare disease treatments: As the awareness and need for rare disease therapeutics increase, Pharming Group NV can leverage its expertise in this area.

Threats

1. Intense competition: The pharmaceutical industry is highly competitive, with established players and new entrants vying for market share.

2. Pricing pressures: Pricing pressures from governments, payers, and insurers can impact the profitability of Pharming Group NV's products.

3. Intellectual property challenges: The risk of patent infringements or challenges to existing patents can threaten Pharming Group NV's market exclusivity.

Pharming Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Pharming Group historical P/E ratio, EBIT multiple, and P/S ratio

Pharming Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Pharming Group shares outstanding

The number of shares of Pharming Group was 758.92 M in 2025. This indicates how many shares Pharming Group is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
641.00 M Stocks
Jan 1, 2022
692.20 M Stocks
Jan 1, 2023
675.00 M Stocks
Jan 1, 2024
740.00 M Stocks
Jan 1, 2025
758.92 M Stocks
Jan 1, 2026 (e)
758.92 M Stocks
Jan 1, 2027 (e)
758.92 M Stocks
Jan 1, 2028 (e)
758.92 M Stocks

Pharming Group stock splits

In Pharming Group's history, there have been no stock splits.

Current Pharming Group forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
92.86 % (13)
Hold
7.14 % (1)
Sell
0.00 % (0)
12M Price Target
2.35
Last Price
1.29
Currency
USD
12M Return Potential
82.36 %
LTM Return
0 %

Pharming Group Analyst Rating Actions

DateFirmActionRatingReliability
3/27/2023
Oppenheimer
Oppenheimer
MaintainedOutperform65
3/27/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
2/22/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
2/16/2023
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Pharming Group Earnings Calls

2025

Pharming Group Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
3/14/20240.01USD-74.93 MUSD-2023 Q4
3/15/2023-USD-59.16 MUSD-2022 Q4
10/27/2022-USD-54.81 MUSD-2022 Q3
8/4/20220.01USD-52.42 MUSD-2022 Q2
3/17/2022-USD-56.67 MUSD-2021 Q4
10/28/2021-USD-54.88 MUSD-2021 Q3
8/5/20210.02USD-68.36 MUSD-2021 Q2
5/13/20210.01USD-62.32 MUSD-2021 Q1
3/4/20210.01USD-61.58 MUSD-2020 Q4
10/29/20200.02USD-56.16 MUSD-2020 Q3

EESG©

Eulerpool ESG Scorecard© for the Pharming Group stock

53/100
22
Environment
74
Social
62
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pharming Group shareholder structure

% Name
2.72606%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
2.11951%
JP Morgan Asset Management
JP Morgan Asset Management
1.49852%
UBS Asset Management (Switzerland)
UBS Asset Management (Switzerland)
0.87027%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.81801%
DWS Investment GmbH
DWS Investment GmbH
0.38831%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited

Pharming Group Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.3%
Float Shares
-
Shares Outstanding
-

Pharming Group Executives and Management Board

15 members · avg. age 59 · 27 % women

Management

FC

Mr. Fabrice Chouraqui

Chief Executive Officer, Executive Director · since 2025

–
KL

Mr. Kenneth Lynard (57)

Chief Financial Officer

–
JW

Mr. Jeroen Wakkerman (56)

Chief Financial Officer

–
MS

Mrs. Mireille Sanders (57)

Chief Operations Officer

–
IB

Ms. Ines Bernal

Chief People Officer

–
RO

Mr. Ruud Van Outersterp (61)

Chief Ethics and Compliance Officer

–

Board of Directors

RP

Dr. Richard Peters (62)

Non-Executive Independent Chairman of the Board

154,000.00 USD
JM

Ms. Jabine Van Der Meijs (59)

Non-Executive Independent Director

109,000.00 USD
BY

Ms. Barbara Yanni (71)

Non-Executive Independent Director

109,000.00 USD
LK

Mr. Leonard Kruimer (67)

Non-Executive Independent Director

104,000.00 USD
SB

Mr. Steven Baert (51)

Non-Executive Independent Director

101,000.00 USD
MP

Dr. Mark Pykett (61)

Non-Executive Independent Director

95,000.00 USD

Pharming Group Supply Chain

Pharming Group Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
5 companies
#Nameβ 1YTrend
1
Kamada
Customer·Biotechnology·IL
-0.30
0.58
0.45
0.18
-0.09
0.42
—
#Nameβ 1YTrend
1
Sanofi
Supplier·Customer·Pharmaceuticals·FR
0.95
0.72
0.48
0.29
-0.16
-0.57
-0.07
2
Omnicom
Supplier·Media·US
-0.56
0.13
0.12
0.41
0.18
-0.39
0.09
3
Novartis
Supplier·Customer·Pharmaceuticals·CH
-0.87
0.13
-0.14
0.04
0.52
0.13
0.44
4
Open Orphan
Supplier·Life Sciences Tools & Services·GB
-0.77
0.29
-0.09
0.11
0.70
0.29
—

Frequently asked questions about Pharming Group

Pharming Group NV operates under a unique business model. The company specializes in the development and commercialization of innovative biotherapeutics using its proprietary technology platform, known as the recombinant human C1 esterase inhibitor (rhC1INH). This technology allows Pharming Group to produce and deliver recombinant human proteins, addressing unmet medical needs in diseases such as hereditary angioedema (HAE) and lysosomal storage disorders. By leveraging their scientific expertise and strategic partnerships, Pharming Group NV aims to improve the quality of life for patients and create value for their stakeholders.

Pharming Group NV is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Pharming Group NV in the market include Biocryst Pharmaceuticals, CSL Behring, Grifols, and Takeda Pharmaceutical Company Limited.

Pharming Group NV is a biopharmaceutical company with a rich history and remarkable background. The company was established in 1988, headquartered in the Netherlands. Pharming focuses on the development and commercialization of innovative protein replacement therapies and precision medicines utilizing its proprietary technology platform. The company is renowned for its pioneering work in the field of recombinant human plasma proteins, particularly Recombinant Human C1 Inhibitor (rhC1INH). Pharming Group NV has successfully developed and marketed these life-saving treatments for hereditary angioedema (HAE) and acquired angioedema (AAE), significantly improving the lives of patients worldwide. With an impressive track record of scientific expertise and substantial market presence, Pharming Group NV continues to be a leading player in the biopharmaceutical industry.

Pharming Group NV has achieved several significant milestones. Notably, the company received approval for its lead product, Ruconest, by regulatory authorities in the United States and Europe. This approval allows Pharming Group NV to market Ruconest for the treatment of acute hereditary angioedema attacks, enhancing the company's market presence. Additionally, Pharming Group NV has successfully expanded Ruconest's sales and commercial footprint, securing distribution agreements in various countries. The company's consistent efforts in research and development have resulted in the exploration of new therapeutic areas, such as Pompe disease. Pharming Group NV's commitment to innovation and attaining regulatory approvals has paved the way for its growth and success in the biopharmaceutical industry.

Pharming Group NV is primarily present in several countries and regions worldwide. The company has a strong presence in the United States, where it operates its North American headquarters. Additionally, Pharming Group NV has a significant presence in Europe, with offices and distribution networks in various countries such as the Netherlands, Germany, France, Italy, and the United Kingdom. Furthermore, the company has expanded its reach into Asia, particularly in important markets like Japan and South Korea. With its global presence, Pharming Group NV is able to effectively deliver its innovative biopharmaceutical products and therapies to patients across different continents.

Pharming Group NV represents values of innovation, collaboration, and patient-centricity. As a leading biotech company, Pharming is committed to developing innovative therapies for patients with unmet medical needs. They prioritize collaboration by partnering with research institutions, healthcare professionals, and patient organizations to advance scientific knowledge. Pharming's corporate philosophy revolves around improving the quality of life for patients through the development and commercialization of novel therapies. Their dedication to scientific excellence, integrity, and global outreach enables them to provide effective and life-changing therapies for patients around the world.

Analysts currently set an average price target of 2.53 USD for the Pharming Group stock (median: 2.35 USD), implying +96.0 % versus the latest price. The consensus is based on 14 analyst ratings.

Pharming Group Analyst Price Targets 2026

14 analysts currently rate the Pharming Group stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Pharming Group to generate revenue of 407.28 M USD and earnings per share of 0.02 USD.

Pharming Group Analyst Price Targets 2026

Converted at the current exchange rate, the Pharming Group share trades at 1.12 EUR (1.29 USD).

The Pharming Group share (PHARM.AS) is listed on 9 stock exchanges, including: Frankfurt (PHGN.F), München (PHGN.MU), Düsseldorf (PHGN.DU), London (0QCO.L), SIX (Zürich) (PHGN.SW), Amsterdam (PHARM.AS).

The Pharming Group NV is a biopharmaceutical company specialized in the development of innovative therapies for rare genetic diseases. The company is based in Leiden, Netherlands and is listed on the Euronext Amsterdam exchange. Pharming's business model is based on the research and development of biopharmaceuticals for the treatment of rare genetic diseases. The company focuses particularly on rare immune system disorders, including Hereditary Angioedema (HAE) and Lymphocytic Varicosis (LV). Pharming also conducts clinical trials for the treatment of other rare diseases. Pharming's products include Ruconest, a recombinant C1 esterase inhibitor (rhC1INH) used for the treatment of HAE. Ruconest is Pharming's flagship product and is marketed globally. The company has also developed a biosimilar version of Ruconest, which is produced under the brand name RucON. Pharming also has a pipeline of future products in development, including a recombinant factor VIII for the treatment of Hemophilia A and a recombinant factor IX for the treatment of Hemophilia B. The company is also working on the development of therapies for the treatment of rarer diseases such as Vascular Ehlers-Danlos Syndrome (EDS). Pharming pursues a diversified business model with a focus on research and development, production, and marketing of biopharmaceuticals. The company also operates its own manufacturing facility to ensure the production of biopharmaceuticals. Pharming also follows a strategic acquisition strategy to expand its product pipeline and increase market presence. Pharming's business model is based on a strong research and development pipeline, efficient production, a differentiated product range, and a strong marketing strategy to increase its presence in the markets. Pharming's focus on rare genetic diseases and continuous innovation in the treatment of these diseases make the company an important player in the biopharmaceutical market.

The expected revenue of Pharming Group is 407.28 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Pharming Group is 17.11 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Pharming Group is currently 57.17. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pharming Group stock.

The price-to-sales ratio (P/S) of Pharming Group is currently 2.40. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pharming Group stock.

The Eulerpool Quality Score for Pharming Group is 5/10.

The ISIN of Pharming Group is NL0010391025. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pharming Group is A1H65A. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pharming Group is PHARM.AS. The ticker symbol is used to trade Pharming Group shares on the stock exchange.

Pharming Group paid dividends every year for the past 0 years.

Pharming Group is assigned to the 'Health' sector.

The dividends of Pharming Group are distributed in USD.

All fundamentals and in-depth analysis of Pharming Group

Our stock analysis for Pharming Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharming Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Pharming Group Stock
Pharming Group Revenue→
Pharming Group Stock
Pharming Group Net Income→
Pharming Group Stock
Pharming Group P/E→
Pharming Group Stock
Pharming Group P/S→
Pharming Group Stock
Pharming Group EBIT→
Pharming Group Stock
Pharming Group Dividend→
Pharming Group Stock
Pharming Group Directors Dealings→
Pharming Group Stock
Pharming Group Stocks→
Pharming Group Stock
Pharming Group Market capitalization→
Pharming Group Stock
Pharming Group Debt→
Pharming Group Stock
Pharming Group Liabilities→
Pharming Group Stock
Pharming Group Equity→
Pharming Group Stock
Pharming Group AAQS→
Pharming Group Stock
Pharming Group Employees→
Pharming Group Stock
Pharming Group ROE→
Pharming Group Stock
Pharming Group ROA→
Pharming Group Stock
Pharming Group ROCE→
Pharming Group Stock
Pharming Group News→
Pharming Group Stock
Pharming Group Analyst Price Targets→